Michael Bertino, MD
Otolaryngology · San Antonio, TXNPI 1114921020
Payments from drug & device makers
Across 25 payments — averaging $29.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$325
- Regeneron Healthcare Solutions, Inc.$149
- GSK$91
- Inspire Medical Systems, Inc.$79
- Medtronic$51
- Fisher & Paykel Healthcare Inc$17
- plus $32 from 2 others
What the payments were for
- Food & beverage$745100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 9 | $325 |
| Regeneron Healthcare Solutions, Inc. | 5 | $149 |
| GSK | 4 | $91 |
| Inspire Medical Systems, Inc. | 2 | $79 |
| Medtronic | 2 | $51 |
| Fisher & Paykel Healthcare Inc | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Resmed Corp | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$122
How this compares
$745 in reported general payments places this provider in the 30th percentile of 729 otolaryngology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dexlansoprazole DrDexlansoprazole | 45 | $15,650 |
| Levocetirizine Dihydrochloride | 801 | $10,961 |
| Fluticasone Propionate | 551 | $10,285 |
| Famotidine | 819 | $8,756 |
| Azelastine Hcl | 150 | $6,770 |
| Pantoprazole Sodium | 582 | $5,718 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 18 | $3,838 |
| Montelukast Sodium | 404 | $3,394 |
| Pilocarpine Hcl | 40 | $3,254 |
| Chlorzoxazone | 71 | $2,985 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 29 | $2,949 |
| Fluocinolone Acetonide Oil | 56 | $2,679 |
| Meclizine Hcl | 211 | $2,644 |
| Naproxen | 165 | $2,487 |
| Ipratropium Bromide | 83 | $2,192 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in San Antonio
- Jeffrey RosenbloomSan Antonio$720K
- Philip ChenSan Antonio$325K
- Nathan HalesSan Antonio$226K
- James AtkinsSan Antonio$205K
- Laurence ChuAustin$37.4M
- Mark ZafereoHouston$7.8M
- Neil GrossHouston$1.5M
- Chad McDuffieFrisco$1.5M
- Ian AlexanderBoerne$999K
- Stephen LaiHouston$968K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.